首頁 > 市場調查報告書 > 醫療設備

電子醫療設備

市場調查報告書

商品編碼

1622124

電子藥品和生物電醫學的全球市場規模：按產品類型、應用、最終用戶、地區、範圍和預測

Global Electroceuticals Bioelectric Medicine Market Size By Product Type, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年11月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

電子藥品及生物電醫學市場規模及預測

2024 年，電子藥品和生物電醫學市場規模為 193.8 億美元，2024 年至 2031 年複合年增長率為 4.5%，預計到 2031 年將達到 275.6 億美元。電療法（生物電醫學）是利用電脈衝控制體內神經迴路並治療疾病的醫療設備。它針對特定的神經和組織，改變神經系統中的電訊號，恢復生理功能並緩解症狀。電治療藥物在各醫學領域有廣泛的應用。它通常用於治療慢性疼痛、神經系統疾病和糖尿病等代謝疾病。例如，植入式神經刺激器可透過阻斷向大腦發出的疼痛訊號來控制慢性疼痛。

在神經病學中，深部腦部刺激（DBS）用於透過調節異常的大腦活動來治療帕金森氏症等運動障礙。

此外，電子製藥還有望用於調節心律的心臟節律和控製糖尿病管理中胰島素分泌的生物電子植入物等應用。

電配製的未來擁有巨大的創新和擴展潛力。小型化、無線技術和生物相容性材料的進步正在提高電子製藥設備的有效性和安全性。研究人員正在探索精神疾病、自體免疫疾病和胃腸道疾病等領域的新應用。

全球電子藥物與生物電醫學市場動態

塑造全球電子藥品和生物電醫藥市場的關鍵市場動態

主要市場驅動因子

對非藥物治療的需求不斷增加：

對藥物副作用和依賴性的擔憂促使患者和醫療保健提供者越來越傾向於非藥物治療。電療法提供針對性的精準治療，可以有效控制慢性疼痛、神經系統疾病和心血管疾病等疾病。根據 NIH 下屬國家補充和綜合健康中心 (NCCIH) 的數據，2020 年至 2023 年間，非藥物疼痛管理技術的使用增加了 25%。

技術進步：

電子、材料科學和神經刺激技術的不斷進步正在推動電療藥物的創新。更小的設備、更長的電池壽命和增強的無線功能正在擴大生物電子醫學在不同醫學專業的適用性和採用。美國國家生物醫學影像與生物工程研究所 (NIBIB) 報告稱，2020 年至 2023 年間，生物電子醫學研究經費將增加 40%。

醫療支出增加：

全球醫療保健支出的增加，加上對具有成本效益的治療方案的需求，正在推動電療法的採用。這些設備有可能透過提供持久的治療效果並最大限度地減少與慢性病相關的住院次數來降低長期醫療保健成本。根據醫療保險和醫療補助服務中心（CMS）的報告，2023年美國醫療保健支出將達到4.3兆美元，年增率為5.4%。

提高認識與接受度：

醫療保健專業人員和患者對生物電療法益處的認識不斷提高，正在推動市場接受度。積極的臨床試驗和患者結果增強了人們對電子藥物作為可行治療選擇的信心，進一步加速了市場的成長和採用。 FDA 報告稱，2020 年至 2023 年間，電療設備的上市前批准數量增加了 35%。

主要問題

監理挑戰：

醫療器材嚴格的監管要求和漫長的審批流程可能會對生物電子醫療領域的市場准入和產品商業化造成障礙。

有限的臨床證據：

需要可靠的臨床證據來證明電療法的安全性、有效性和長期益處仍然是一個挑戰。數據不足或臨床結果混雜可能會阻礙醫療保健提供者和患者的採用。

成本高，價格實惠：

與電療設備相關的高成本（包括開發、製造和維護）可能會限制市場成長和可近性，特別是在醫療保健預算有限的地區。

技術複雜性：

生物電醫療技術（包括設備植入、編程和維護）的複雜性需要對醫療保健專業人員進行專門培訓，並且可能對傳播和患者接受度帶來挑戰。

競爭格局：

電子藥品市場中現有醫療器材公司與新興新創公司之間的激烈競爭可能會導致定價壓力、創新障礙和整合，從而影響市場動態和獲利能力。

主要趨勢

個人化醫療：

利用診斷、遺傳學和數據分析方面的進步來優化治療結果並根據患者個體情況進行個人化電子藥物治療的趨勢日益明顯。根據美國國立衛生研究院（NIH）預測，2020年至2023年精準醫學研究經費將增加35%，2023年達18億美元。

無線與穿戴式科技：

將無線通訊和穿戴式技術整合到電子製藥中，可實現遠端監控、即時數據收集和患者參與，從而提高治療效果和患者便利性。根據美國疾病管制與預防中心 (CDC) 2023 年的報告，45% 患有慢性病的成年人使用某種可穿戴醫療技術，高於 2020 年的 32%。

擴展到新的治療領域：

生物電子醫學正在從疼痛管理和神經系統疾病等傳統應用擴展到心臟病學、胃腸病學和腫瘤學等新的治療領域，從而擴大了市場潛力。 2024年2月，Electrocore進入胃腸病學市場，並獲得FDA核准用於治療胃食道逆流（GERD）的非侵入性迷走神經刺激療法。

Electroceuticals Bioelectric Medicine Market size was valued at USD 19.38 Billion in 2024 and is projected to reach USD 27.56 Billion by 2031, growing at a CAGR of 4.5% from 2024 to 2031. Electroceuticals, or bioelectric medicine, are medical devices that use electrical impulses to modulate neural circuits in the body to treat diseases. They target specific nerves or tissues, restoring physiological function or alleviating symptoms by altering electrical signals in the nervous system. Electroceuticals have diverse applications across various medical fields. They are commonly used in the treatment of chronic pain, neurological disorders, and metabolic conditions such as diabetes. For example, implantable neurostimulators can be used to manage chronic pain by blocking pain signals to the brain.

In neurology, deep brain stimulation (DBS) is employed to treat movement disorders like Parkinson's disease by modulating abnormal brain activity.

Additionally, electroceuticals show promise in applications such as cardiac pacing to regulate heart rhythms and bioelectronic implants to control insulin release in diabetes management.

The future of electroceuticals holds significant potential for innovation and expansion. Advancements in miniaturization, wireless technology, and biocompatible materials are enhancing the effectiveness and safety of electroceutical devices. Researchers are exploring new applications in areas such as mental health disorders, autoimmune diseases, and gastrointestinal disorders.

Global Electroceuticals Bioelectric Medicine Market Dynamics

The key market dynamics that are shaping the global electroceuticals bioelectric medicine market include:

Key Market Drivers

Increasing Demand for Non-pharmacological Therapies:

There is a growing preference among patients and healthcare providers for non-pharmacological treatments due to concerns over drug side effects and dependency. Electroceuticals offer targeted, precise therapies that can effectively manage conditions such as chronic pain, neurological disorders, and cardiovascular diseases. According to the National Center for Complementary and Integrative Health (NCCIH), a division of the NIH, the use of non-pharmacological pain management techniques increased by 25% between 2020 and 2023.

Technological Advancements:

Continuous advancements in electronics, materials science, and neurostimulation techniques are driving innovation in electroceuticals. Miniaturization of devices, improved battery life, and enhanced wireless capabilities are expanding the applicability and adoption of bioelectric medicine across diverse medical specialties. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) reported a 40% increase in funding for bioelectronic medicine research between 2020 and 2023.

Rising Healthcare Expenditure:

Increasing healthcare expenditure globally, coupled with the need for cost-effective treatment options, is boosting the adoption of electroceuticals. These devices can potentially reduce long-term healthcare costs by offering long-lasting therapeutic benefits and minimizing hospitalizations related to chronic conditions. The Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare spending reached $4.3 trillion in 2023, with a 5.4% annual growth rate.

Growing Awareness and Acceptance:

Rising awareness among healthcare professionals and patients about the benefits of bioelectric therapies is driving market acceptance. Clinical studies and successful patient outcomes are increasing confidence in electroceuticals as viable treatment options, further accelerating market growth and adoption. The FDA reported a 35% increase in premarket approvals for electroceutical devices between 2020 and 2023.

Key Challenges:

Regulatory Challenges:

Stringent regulatory requirements and lengthy approval processes for medical devices can pose barriers to market entry and product commercialization in the bioelectric medicine sector.

Limited Clinical Evidence:

The need for robust clinical evidence to demonstrate safety, efficacy, and long-term benefits of electroceutical therapies remains a challenge. Insufficient data or mixed clinical outcomes may hinder adoption by healthcare providers and patients.

High Costs and Affordability:

The high costs associated with electroceutical devices, including development, manufacturing, and maintenance, can limit market growth and accessibility, particularly in regions with constrained healthcare budgets.

Technological Complexity:

The complexity of bioelectric medicine technologies, including device implantation, programming, and maintenance, requires specialized training for healthcare professionals and may pose challenges in widespread adoption and patient acceptance.

Competitive Landscape:

Intense competition among established medical device companies and emerging startups in the electroceuticals market can lead to pricing pressures, innovation barriers, and consolidation, impacting market dynamics and profitability.

Key Trends

Personalized Medicine:

There is a growing trend towards personalized electroceutical therapies tailored to individual patient profiles, leveraging advancements in diagnostics, genetics, and data analytics to optimize treatment outcomes. According to the National Institutes of Health (NIH), funding for precision medicine research increased by 35% between 2020 and 2023, reaching $1.8 billion in 2023.

Wireless and Wearable Technologies:

Integration of wireless communication and wearable technologies in electroceuticals allows for remote monitoring, real-time data collection, and patient engagement, enhancing treatment efficacy and patient convenience. A 2023 report from the Centers for Disease Control and Prevention (CDC) found that 45% of adults with chronic conditions used some form of wearable health technology, up from 32% in 2020.

Expansion into New Therapeutic Areas:

Bioelectric medicine is expanding beyond traditional applications like pain management and neurological disorders into new therapeutic areas such as cardiology, gastroenterology, and oncology, broadening its market potential. In February 2024, electroCore received FDA clearance for its non-invasive vagus nerve stimulation therapy to treat gastroesophageal reflux disease (GERD), marking its entry into the gastroenterology market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Electroceuticals Bioelectric Medicine Market Regional Analysis

Here is a more detailed regional analysis of the global electroceuticals bioelectric medicine market:

North America

North America dominating the electroceuticals market due to several key factors. The region benefits from a robust healthcare infrastructure that facilitates adoption of advanced medical technologies. The American Hospital Association's 2023 annual survey revealed that 68% of U.S. hospitals had implemented at least one form of electroceutical therapy, up from 52% in 2020.

Technological advancements in neurostimulation and cardiac therapies are particularly prominent, supported by substantial healthcare expenditure and a proactive regulatory environment that fosters innovation. The National Institutes of Health (NIH) allocated USD 985 Million to neurotechnology research in fiscal year 2023, a 15% increase from 2021.

Strong research and development activities further enhance North America's position, driving continuous advancement and application of bioelectric medicine in clinical settings. The National Science Foundation reported that private sector R&D investment in medical equipment and supplies, including electroceuticals, reached USD 21.8 Billion in 2023, a 9.5% increase from 2021.

Asia Pacific

Asia Pacific is indeed emerging as a rapidly growing market for electroceuticals. The region's growth is fueled by increasing investments in healthcare infrastructure and technology, driven by countries such as China, Japan, and India. According to the World Health Organization (WHO), healthcare spending in the Asia Pacific region increased by an average of 7.2% annually between 2020 and 2023.

These nations are experiencing a rising prevalence of chronic diseases and expanding medical tourism, which further boosts demand for advanced medical treatments, including neuromodulation and cardiac devices. India's Ministry of Tourism reported that medical visa arrivals increased by 32% in 2023 compared to 2021, with neurology and cardiology being among the top specialties sought by international patients.

This trend underscores Asia Pacific's evolving role as a key player in the global electroceuticals market, supported by efforts to enhance healthcare access and technological capabilities. The China National Medical Products Administration (NMPA) approved 28 new electroceutical devices in 2023, compared to 18 in 2021, indicating accelerated innovation and regulatory support.

Global Electroceuticals Bioelectric Medicine Market: Segmentation Analysis

The Global Electroceuticals Bioelectric Medicine Market is Segmented on the basis of Product Type, Application, End-User, and Geography.

Electroceuticals Bioelectric Medicine Market, By Application

Pain Management
Neurological Disorders
Cardiac Disorders
Gastrointestinal Disorders

Based on Application, the Global Electroceuticals Bioelectric Medicine Market is bifurcated into Pain Management, Neurological Disorders, Cardiac Disorders, and Gastrointestinal Disorders. In the electroceuticals bioelectric medicine market, neurological disorders currently dominate as the leading application segment. This dominance is driven by the widespread adoption of neurostimulation therapies for conditions such as Parkinson's disease, epilepsy, and chronic pain syndromes. Neurological disorders benefit significantly from the precise targeting and modulation of neural circuits offered by bioelectric medicine, enhancing patient outcomes and quality of life. The Cardiac Disorders segment is rapidly growing, fueled by advancements in cardiac neuromodulation techniques and devices aimed at managing arrhythmias, heart failure, and other cardiovascular conditions.

Electroceuticals Bioelectric Medicine Market, By Product Type

Implantable Electroceutical Devices
Non-invasive Electroceutical Devices

Based on Product Type, the Global Electroceuticals Bioelectric Medicine Market is bifurcated into Implantable Electroceutical Devices and Non-invasive Electroceutical Devices. In the market, implantable electroceutical devices currently dominate as the leading product type segment. These devices, such as neurostimulators and implantable cardiac devices, offer targeted therapy directly at the site of action within the body, providing long-term management of chronic conditions like Parkinson's disease and cardiac arrhythmias. The precision and effectiveness of implantable devices contribute to their widespread adoption and market dominance. The Non-invasive Electroceutical Devices segment is rapidly growing, driven by advancements in technologies like transcutaneous electrical nerve stimulation (TENS) and external neuromodulation devices.

Electroceuticals Bioelectric Medicine Market, By End-User

Hospitals and Clinics
Ambulatory Surgical Centers
Research Institutes

Based on End-User, the Global Electroceuticals Bioelectric Medicine Market is bifurcated into Hospitals and Clinics, Ambulatory Surgical Centers, Research Institutes. In the electroceuticals bioelectric medicine market, hospitals and clinics is expected to dominate the leading end-user segment. Hospitals and clinics are primary settings for the diagnosis, treatment, and management of chronic conditions that benefit from bioelectric therapies, such as neurological disorders and cardiac diseases. These healthcare facilities have the infrastructure and expertise to support the use of electroceutical devices, driving their widespread adoption and market dominance. The Ambulatory Surgical Centers segment is rapidly growing, fueled by the increasing trend towards outpatient procedures and minimally invasive treatments using electroceutical devices.

Electroceuticals Bioelectric Medicine Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Electroceuticals Bioelectric Medicine Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the market, North America is anticipated to lead geographical segment. This region benefits from a mature healthcare infrastructure, significant investments in research and development, and a proactive regulatory environment that supports the adoption of bioelectric medicine. North America's dominance is further bolstered by high healthcare expenditure and robust market penetration of advanced neurostimulation and cardiac devices. Asia Pacific is rapidly growing in the electroceuticals market, driven by increasing healthcare investments, rising prevalence of chronic diseases, and expanding adoption of advanced medical technologies.

Key Players

The "Global Electroceuticals Bioelectric Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Inc., LivaNova PLC, Cochlear Ltd., Neuronetics, Inc., Second Sight Medical Products, Inc., NeuroPace, Inc., and BIOTRONIK SE & Co. KG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Electroceuticals Bioelectric Medicine Market Key Developments

In March 2024, Medtronic announced the FDA approval of its next-generation closed-loop deep brain stimulation system for Parkinson's disease. The system features adaptive stimulation based on real-time brain signals, marking a significant advancement in personalized neuromodulation therapy.
In January 2024, Boston Scientific launched a new spinal cord stimulation platform with advanced pain targeting algorithms. The system incorporates AI-driven technology to optimize stimulation parameters based on individual patient responses, enhancing treatment efficacy for chronic pain conditions.
In November 2023, Abbott Laboratories introduced a wireless neuromodulation system for chronic pain management. The device allows patients to control and monitor their therapy via a smartphone app, improving patient engagement and treatment adherence.
In September 2023, Nevro Corp. received FDA approval for an expanded indication of its high-frequency spinal cord stimulation therapy to include treatment of painful diabetic neuropathy. This approval opens up a significant new market for the company's electroceutical technology.
In July 2023, electroCore secured FDA clearance for its non-invasive vagus nerve stimulation therapy to treat gastroesophageal reflux disease (GERD). This marks the company's entry into the gastroenterology market, broadening the application of bioelectric medicine beyond its traditional domains.
In April 2023, SetPoint Medical initiated a Phase II clinical trial for its bioelectronic therapy in treating inflammatory bowel disease. This development represents a significant step in expanding the application of electroceuticals to autoimmune disorders beyond rheumatoid arthritis.